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Abstract  19 
Globally, there is a continuous rise in the older population (over 65 years), particularly in 20 
developed countries.  As many diseases are age-related, older adults represent a highly 21 
heterogeneous cohort.  This presents a major challenge for both the pharmaceutical industry 22 
and healthcare professionals. The purpose of this research was to attract attention towards 23 
the appropriateness of geriatric formulations by investigating the dosage form attributes of 24 
currently UK licensed cardiovascular and Parkinson’s disease drug products.  Medication 25 
available in the UK for cardiovascular disorders and Parkinson’s disease were screened and 26 
the available formulations, packaging and patient information leaflets of these medicines 27 
were analysed, with the goal of raising awareness of the need to cater for elderly patients 28 
with increasing difficulty in managing their medication. It emerged that although 29 
cardiovascular disorders and Parkinson’s disease are more prevalent in older people, many 30 
treatment options have not been optimised for this cohort.  In particular, older patient centred 31 
dosage forms, specific dosing requirements, excipients, patient-friendly packaging and easy-32 
to-follow patient information were highlighted as areas to be considered in order to optimise 33 
health outcomes in the ageing population. 34 
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Older people, defined as individuals over 65 years old, represent approximately 17.2% of the 41 
total community population in the United Kingdom (UK) and this is expected to increase to 42 
22.4% by 2032 (AgeUK, 2014).  Similarly, older people constitute around 17% of the total 43 
community population in Europe and this is predicted to increase to 30% in 2050 (European 44 
Medicines Agency, 2013).  According the Age UK 2014 report on later life, cardiovascular 45 
disease (CVD) is the greatest causes of death in the UK in people over 65 years (AgeUK, 46 
2014).  Parkinson’s disease (PD) is another fatal disease that is prevalent in the older 47 
population, with almost two thirds of all PD cases reported in those over 70 years old 48 
(Meara, 2000).  Therefore, in the present study, pharmaceutical products listed in the British 49 
National Formulary (BNF) for CVD and PD were screened in order to determine the 50 
suitability of the formulations and associated information for older people.  It has been 51 
previously reported that up to 50% of patients do not use their medication as prescribed 52 
(National Collaborating Centre for Primary Care, 2009).  By screening the available 53 
information on formulations from two areas of particular importance in prescribing for older 54 
patients, this research aims to assess the appropriateness of dosage forms with respect to 55 
the older population. 56 
 57 
All products listed in the Cardiovascular System and Parkinsonism and Related Disorders 58 
sections of the BNF (Joint Formulary Committee, 2013) were included for analysis.  The 59 
available data were then compiled from relevant UK reference sources - the BNF, Summary 60 
of Products Characteristics (SmPC) and Patient Information Leaflets (PILS) (Joint Formulary 61 
Committee, 2013).  In the BNF, 262 products were listed under cardiovascular system and 62 
41 products were listed under Parkinsonism and related disorders.  The SmPCs as well as 63 
relevant PILs were screened and aspects considered significant in the optimisation of 64 
formulations for CVDs (Table 1) and PD (Table 2) in elderly patients were identified for 65 
analysis.  66 
 67 
4 
 
The classification of dosage forms for CVD and PD drug products are presented in Table 3.  68 
Of the listed cardiovascular drug products, 48% specified general posology adjustment 69 
guidelines based on both renal and hepatic function (Fig.1).  Posology adjustments of the 70 
cardiovascular formulations were mainly based on renal and hepatic impairment.  Renal and 71 
hepatic functions are often reduced in older patients, affecting drug metabolism and 72 
clearance (Mangoni and Jackson, 2004).  However, there are other age-related changes that 73 
can influence the pharmacokinetic and pharmacodynamic parameters of medication.  For 74 
example, older patients are often more sensitive to cardiovascular drugs such as digoxin and 75 
warfarin, both of which have a narrow therapeutic index, due to a reduction in apparent 76 
volume of distribution of these agents.  This considerably increases serum concentration and 77 
therefore, toxicology and adverse effects.  On the contrary, the efficacy of adrenoceptor 78 
blocking agents declines with age and careful dose titration is required.  However, these 79 
factors were considered for less than half of the available cardiovascular dosage forms, with 80 
30 providing neither specific adjustments for older patients nor any information regarding 81 
posology adjustments.  This suggests that more academic and industrial efforts are required 82 
to optimise the efficacy of medicines for the older population (Ford, 2000; Mangoni and 83 
Jackson, 2004).  Clinical trials often exclude older patients based on age, concomitant 84 
conditions, polypharmacy, frailty or the higher costs associated with recruiting and 85 
maintaining elderly during clinical trials.  However, the extrapolation of clinical findings to 86 
include patients outside the tested age range does not offer a true representation of these 87 
groups.  Clinical studies for older patients are required to maintain the safety of elderly 88 
participants and to obtain valid professional data regarding those patients that can be used 89 
by healthcare professionals (Cherubini et al., 2010; ICH Steering Committee, 2010). 90 
 91 
Of the listed CVD products, 40% specified dose recommendations that were adjusted for 92 
older patients, taking into account factors such as comorbidity, polypharmacy, increased 93 
vulnerability to adverse effects and other age-related physiological changes that can impact 94 
the pharmacodynamic profile and tolerability of the patient.  The prevalence of modified 95 
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release formulations, fixed-dose combinations (FDCs) and “risky” excipients (for example 96 
propylene glycol or sodium) are also shown in Fig. 1.  Polypharmacy is common in older 97 
patients.  While multi-drug prescribing is often necessary in the treatment of age-related 98 
conditions including CVD, it can significantly increase the complexity of dosing regimens and 99 
contribute to non-compliance (Hilmer et al., 2007).  FDCs allow multiple drugs to be 100 
delivered in a single entity.  Increasing the number of licensed FDCs would be beneficial in 101 
reducing the number of medications required in conditions such as CVD, when the level of 102 
concomitant prescribing is high (Bangalore et al., 2007; Martial et al., 2013).  Modified 103 
release formulations offer a prolonged action in the body, which in turn may reduce the 104 
frequency of dose administration, particularly in drugs with short biological half-lives.  105 
Reducing the complexity of drug regimens by minimising dose frequency has been shown to 106 
reduce the incidence of forgotten dose and increases compliance (Collett and Moreton, 107 
2007). 108 
 109 
Three types of packaging were identified for PD medication.  The majority of formulations 110 
(64%) were packaged in a glass bottle with either a screw, tamper evident or child resistant 111 
closure, with 46% packed in blisters and 6% packaged in a container with a snap-lid.  112 
Packaging is an essential tool in the preservation of safety, stability and identity of 113 
pharmaceutical preparations.  It can also affect the ability or willingness of a patient to take 114 
their medication and can therefore, influence compliance (Murdan, 2013).  Previous 115 
research has demonstrated that many elderly people have difficulty opening medication 116 
containers (Atkin et al., 1994; Philbert et al., 2014).  In a recently published survey 117 
investigating medicine packaging in older people, Philbert et al. (2014) found that one in four 118 
individuals over 65 experienced difficulties opening their medication packaging.  These 119 
issues are compounded by age-related conditions such as PD and rheumatic disorders, 120 
which cause dexterity difficulties.  There is strong correlation between Parkinsonism and a 121 
reduced ability to handle different types of pharmaceutical packaging, in particular snap-lids, 122 
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followed by screw-cap bottles and, to a lesser extent, blister packs (Beckman et al., 2005).  123 
Therefore, it appears to be a serious oversight that some PD medication is packaged in 124 
these formats. 125 
 126 
PILs were available for 39 of the 41 screened preparations; the availability of elderly-specific 127 
information is shown in Fig. 2.  This information was limited for PD medication, with less than 128 
13% containing pictograms to assist in portraying information (Fig. 2).  Whilst patient-specific 129 
information may be explained by the prescriber or pharmacist, inclusion of standard 130 
information in the PILs may eliminate confusion, particularly as older patients are more likely 131 
to have cognitive impairment, anxiety and poor vision, all of which will make it more difficult 132 
to remember oral instructions and read written medication labels (Weinman, 1990). 133 
 134 
The majority of cardiovascular formulations were formulated as solid oral dosage forms, 135 
which is supported by previous research that found between 65% and 70% of available 136 
drugs are formulated as solid oral dosage forms (Schiele et al., 2013).  Oral dosage forms, 137 
particularly solid formulations, tend to have higher stability, are easier to manufacture and 138 
handle, cheaper compared to other dosage forms and more palatable.  However, in elderly 139 
patients, such dosage forms are not always suitable.  The prevalence of dysphagia 140 
increases with age and CVDs such as hypertension and hypercholesterolemia increase the 141 
risk of stroke, which may further exacerbate swallowing difficulties.  This may make it difficult 142 
for patients to take the medication required to control their condition, such as warfarin and 143 
aspirin, which are only available as solid oral dosage forms (Schiele et al., 2013).  In 144 
addition, complications associated with PD include dysphagia and motor disorders, which 145 
can reduce the success of therapy and outweigh the convenience of oral drug delivery 146 
(Meara, 2000; Monteiro et al., 2014).  In the present study, many of the tablets for PD were 147 
available only as a coated formulation to be swallowed whole.  Challenges associated with 148 
swallowing such a tablet whole may result in the incorrect modification of these dosage 149 
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forms by patients and subsequent reduced efficacy and safety issues (Schiele et al., 2013).  150 
There are several alternative drug delivery systems that can minimise swallowing difficulties.  151 
These include sublingual or buccal tablets, soluble film strips, orodispersible tablets, 152 
crushable tablets and capsules that can be opened and mixed with soft food (Breitkreutz and 153 
Boos, 2007; Dey and Maiti, 2010).  154 
 155 
In the present study, nearly half of the screened CVD formulations contained sodium.  In 156 
some cases, the amount of sodium in effervescent, dispersible and soluble tablets 157 
prescribed for cardiovascular disorders was found to be higher than the recommended UK 158 
daily sodium intake of 2.4 g (104 mmol) for adults.  High sodium consumption increases 159 
water retention by disturbing the electrolyte balance in the body, increasing the risk of many 160 
cardiovascular conditions such as hypertension, stroke and heart failure, especially in older 161 
patients (George et al., 2013).  Further, compounds such as sodium bicarbonate, which acts 162 
as an alkalinising agent in some formulations, can aggravate cardiovascular events including 163 
chronic heart failure in the elderly population (Turner et al., 2013).  Therefore, it is important 164 
that pharmaceutical manufacturers consider this when developing formulations and that 165 
prescribers, pharmacists and patients are aware of the potential toxicity of excipients in 166 
dosage forms and select appropriate dosage forms accordingly.  To facilitate this, the 167 
sodium content in pharmaceutical products should be clearly labelled, as is the case in the 168 
food industry (George et al., 2013; Tuleu and Wright, 2013). 169 
 170 
This study highlights the paucity of formulations specifically designed for the elderly 171 
population, even in conditions such as CVD and PD, which are more prevalent in older 172 
people.  Specific age related limitations including comorbidity, polypharmacy, dysphagia, 173 
impaired manual dexterity and visual and cognitive impairments need to be considered in 174 
relation to their impact on the complexity of the drug regimen, compliance, type of the 175 
dosage forms, posology adjustment, packaging and the layout of patient information.  The 176 
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development of novel fixed-dose combinations and modified release formulations will assist 177 
in the simplification of medication regimens and improve patient compliance. 178 
 179 
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Graphical Abstract (for review)
Table 1.  Pharmaceutical formulation aspects considered significant in the screening 
of dosage forms with respect to elderly patients receiving medication for 
cardiovascular disorders. 
BNF classification 
Therapeutic indication(s) 
Active pharmaceutical ingredient(s) 
Available dosage forms 
Therapy type (mono or fixed dose combinations (FDCs)) 
Dose frequency (mono- or multi- dose) 
Potential “risky excipients” (propylene glycol, sodium) 
Tablet scoring/ability to be halved 
Drug release profile (immediate/modified release) 
Coating type 
Age range 
Minimum age 
Elderly-specific section 
Packaging type 
Storage conditions 
Name of marketing authorisation holder 
Information source and additional comments 
 
  
Table(s)
Table 2.  Pharmaceutical formulation aspects considered significant in the screening 
of dosage forms with respect to elderly patients receiving medication for Parkinson’s 
disease. 
BNF classification 
Therapeutic indication(s) 
Active pharmaceutical ingredient(s) 
Available dosage forms 
Method of administration 
Therapy type (mono or fixed dose combinations (FDCs)) 
Drug release (immediate/modified release) 
Packaging 
Elderly-specific section 
Definition of elderly 
Pictogram 
Specific warnings for elderly 
 
 
  
Table 3.  Classification of screened dosage forms and route of administration for 
cardiovascular disorders (CVD) and Parkinson’s disease (PD).  Observations are 
reported as number of drug products (n) and percentage of oral, sublingual, 
parenteral, topical or other formulations (%). 
 
 
 
  
Route of administration CVD (n = 262) PD (n = 41) 
Oral, n (%) 198 (76) 33 (80) 
 Tablets, n 150 20 
 Chewable tablets, n 1 - 
 Dispersible tablets, n 1 1 
 Orally disintegrating 
tablet 
- 1 
 Capsules, n 30 5 
 Liquid, n 13 6 
 Sachet/powder, n 3 - 
   
Sublingual, n (%) 3 (1.1) - 
 Tablet 1 - 
 Spray 2 - 
   
Parenteral, n (%) 58 (22) 7 (17) 
 IV injection, n 17 - 
 IV infusion, n 14 - 
 IV injection or infusion, n 17 - 
 IV/SC injection or 
infusion, n 
1 - 
 IV/IM injection, n - 1 
 IM injection, n 3 3 
 SC injection, n 5 2 
 Intra-ocular injection, n 1  
   
Topical, n (%) 2 (0.76) 1 (2) 
 Ointment, n 1  
 Patches, n 1 1 
   
Other 1 (0.38) 1 (2) 
 Pulmonary, n (%) 1 - 
 Intestinal gel, n (%) - 1 
IV = intravenous; IM = intramuscular; SC = subcutaneous 
Fig. 1  Prevalence of key characteristics for each of the CVD formulations, presented 
as a percentage of the 262 formulations screened.  
 
Fig. 2  The availability of elderly specific information in the PILs of formulations for 
Parkinson’s disease.  
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